Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA)

Tykvart, Jan; Navrátil, Václav; Sedlák, František; Corey, Eva; Colombatti, Marco; Fracasso, Giulio; F, Koukolík; Bařinka, Cyril; Šácha, Pavel; Konvalinka, Jan

doi:10.1002/pros.22887

Cited by 35 publications

(43 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the following years great efforts were undertaken to develop mAbs against the extracellular domain of PSMA. Summarizing these efforts, numerous papers describing in detail the mAbs different characteristics have been published [72][73][74][75][76][77]. Of these, the mAbs J591, J533, J415, D2B, 107-1A4, E99, 3/A12, 3/E7, 3/F11 and 3E6 have been shown to bind the most efficiently to cell-surface PSMA.…”

Section: Antibodiesmentioning

confidence: 99%

Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives

et al. 2020

View full text Add to dashboard Cite

Prostate cancer is the most commonly diagnosed malignancy in men and the second leading cause of cancer-related deaths in Western civilization. Although localized prostate cancer can be treated effectively in different ways, almost all patients progress to the incurable metastatic castration-resistant prostate cancer. Due to the significant mortality and morbidity rate associated with the progression of this disease, there is an urgent need for new and targeted treatments. In this review, we summarize the recent advances in research on identification of prostate tissue-specific antigens for targeted therapy, generation of highly specific and selective molecules targeting these antigens, availability of therapeutic radionuclides for widespread medical applications, and recent achievements in the development of new-generation small-molecule inhibitors and antibody-based strategies for targeted prostate cancer therapy with alpha-, beta-, and Auger electron-emitting radionuclides.

show abstract

Section: Antibodiesmentioning

confidence: 99%

Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Therefore, we did not think that these molecules are good targets for therapy. PSMA is the only TAA with high levels of cell surface expression on 100% of cancer cells but 0% of normal cells [13]. We wonder if there are any other TAAs that are specifically utilized in the tumorigenesis of a specific type of cancer.…”

Section: Discussionmentioning

confidence: 99%

Classification of 27 Tumor-Associated Antigens by Histochemical Analysis of 36 Freshly Resected Lung Cancer Tissues

Kurosawa

Sugiura

Hattori

et al. 2016

IJMS

View full text Add to dashboard Cite

In previous studies, we identified 29 tumor-associated antigens (TAAs) and isolated 488 human monoclonal antibodies (mAbs) that specifically bind to one of the 29 TAAs. In the present study, we performed histochemical analysis of 36 freshly resected lung cancer tissues by using 60 mAbs against 27 TAAs. Comparison of the staining patterns of tumor cells, bronchial epithelial cells, and normal pulmonary alveolus cells and interalveolar septum allowed us to determine the type and location of cells that express target molecules, as well as the degree of expression. The patterns were classified into 7 categories. While multiple Abs were used against certain TAAs, the differences observed among them should be derived from differences in the binding activity and/or the epitope. Thus, such data indicate the versatility of respective clones as anti-cancer drugs. Although the information obtained was limited to the lung and bronchial tube, bronchial epithelial cells represent normal growing cells, and therefore, the data are informative. The results indicate that 9 of the 27 TAAs are suitable targets for therapeutic Abs. These 9 Ags include EGFR, HER2, TfR, and integrin α6β4. Based on our findings, a pharmaceutical company has started to develop anti-cancer drugs by using Abs to TfR and integrin α6β4. HGFR, PTP-LAR, CD147, CDCP1, and integrin αvβ3 are also appropriate targets for therapeutic purposes.

show abstract

“…Immunohistochemistry of human and mouse samples was performed as previously described with minor modifications. After fixation in 10% buffered formalin, tissues were dehydrated using graded ethanol followed by xylene immersion and paraffin embedding.…”

Section: Methodsmentioning

confidence: 99%

“…Immunohistochemistry of human and mouse samples was performed as previously described 35 To generate Folh1 −/− mice, we designed TALENs that specifically cleaved exon 11 of the Folh1 gene within the sequence encoding the PSMA/GCPII active site ( Figure 1A). Two independent TALEN microinjections into male nuclei of C57BL/6NCrl zygotes were performed, resulting in 65 transgenic mice of the F0 generation.…”

Section: Histopathology and Immunohistochemistrymentioning

confidence: 99%

A novel PSMA/GCPII‐deficient mouse model shows enlarged seminal vesicles upon aging

et al. 2018

View full text Add to dashboard Cite

show abstract

Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA)

Abstract: This comparative analysis provides the first detailed quantitative characterization of the most commonly used mAbs against GCPII and can serve as a guideline for the scientific community to use them in a proper and efficient way.

Cited by 35 publications

References 62 publications

Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives

Targeted Radionuclide Therapy of Prostate Cancer—From Basic Research to Clinical Perspectives

Classification of 27 Tumor-Associated Antigens by Histochemical Analysis of 36 Freshly Resected Lung Cancer Tissues

A novel PSMA/GCPII‐deficient mouse model shows enlarged seminal vesicles upon aging

Contact Info

Product

Resources

About